Tanios S. Bekaii-Saab, MD, Discusses Key Findings From a Genomic and Immune Profiling Study in Intrahepatic Cholangiocarcinoma

Video

At ASCO 2021, Tanios S. Bekaii-Saab, MD, talked about some of his research in patients with IDH1/2–positive cholangiocarcinoma presented at the meeting.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, of Mayo Clinic, about key findings from a genomic and immune profiling study in patients with intrahepatic cholangiocarcinoma. Specifically, he examines the incidence of IDH1/2 mutations and key findings related to these genetic abnormalities.

Transcript:

What we essentially found in our study that [was] presented at ASCO was that close to 20% of patients will have IDH1 or IDH2 [mutations], [which] is very similar to [what] we expected. Two things about IDH1: It seems that IDH1/2 are mutually exclusive, and that is good to see, [as] drivers do not co-occur, at least [in terms of] the drivers that are targetable and can arrest development of the cancer. The other thing is, interestingly, if you have an IDH1 or an IDH2 mutation, you are less likely to find other targetable alterations. You will almost never find an FGFR2 fusion, for example.

Reference

Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study. J Clin Oncol. 2021;39(suppl 15):4009. doi:10.1200/JCO.2021.39.15_suppl.4009

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content